Philip J. Breen

High Impact

Researcher

UAMS

Last publication 2023 Last refreshed 2026-05-16

faculty

20 h-index 49 pubs 1,895 cited

Research Areas

Links

Research Group UAMS TRI Profile

OverviewAI-generated summary

Philip J. Breen's research focuses on the intersection of chemistry, pharmacology, and biology, with a particular emphasis on understanding molecular mechanisms and developing potential therapeutic agents. His work has explored the radioprotective effects of tocotrienols, investigating their dual roles as antioxidants and signaling molecules across multiple organ systems. Breen has also investigated compounds with antileukemic properties derived from plant-plant interactions.

His laboratory has conducted pharmacokinetic studies, including an analysis of morphine-6-O-sulfate in rat plasma and brain. Furthermore, Breen's research group has been involved in the development of novel tocotrienol analogues, such as tocoflexol, for potential use as radiomitigators. His scholarship is evidenced by a high-impact designation, with 49 publications and 1,880 citations, and an h-index of 20. He leads a research group and collaborates with several faculty members at the University of Arkansas for Medical Sciences, including Darin E. Jones, David E. Mery, Edward J. Selvik, and Nükhet Aykin‐Burns.

Metrics

h-index: 20
Publications: 49
Citations: 1,895

Selected Publications

Tocotrienols Provide Radioprotection to Multiple Organ Systems through Complementary Mechanisms of Antioxidant and Signaling Effects (2023)

9 citations DOI OpenAlex
466 Development of a novel tocotrienol analogue, tocoflexol, as a radiomitigator (2023)

DOI OpenAlex
Analysis of Plant–Plant Interactions Reveals the Presence of Potent Antileukemic Compounds (2022)

1 citation DOI OpenAlex
A pharmacokinetic study of <scp>morphine‐6‐<i>O</i></scp>‐sulfate in rat plasma and brain (2021)

1 citation DOI OpenAlex